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doi:10.1016/j.ejvs.2009.06.004Abstract Purpose: To compare the mid-term results following the use of bifurcated (ABIS)
and aorto-uniiliac (AUIS) endovascular devices in the treatment of abdominal aortic aneurysms
(AAA) in a population of patients deemed to be at high risk for open surgery.
Material and methods: Over a 4 year period (January 2003 to December 2007), 447 underwent
elective endovascular aneurysm repair (EVAR) using ZENITH stent-grafts. Group I comprised
patients treated using the AUIS (nZ 124), and group II those receiving ABIS (nZ 323).
Outcome measures included the assisted technical success rate, perioperative mortality,
major complications, freedom from reintervention, and primary and secondary patencies.
Factors associated with mid-term clinical failures were determined using univariate and multi-
variate analyses.
Results: The assisted primary technical success rate was 94% and 99% in groups I and II respec-
tively (pZ .002). Major perioperative complications occurred in 13 group I patients (10%) vs.
12 group II patients (4%) (pZ .005). The 30-day mortality rate was 3.2% vs.1.5% (pZ 0.2). TASC
C and D iliac lesions significantly increased the risk of major perioperative complications (35%
vs. 3%; ORZ 14.94; 95% CI: 5.75 to 38.78; p< .0001). During the follow-up period (median 24
months), secondary procedures were required in 11% and 5% of group I and group II patients
respectively (pZ .01). Freedom from reintervention at 12, 24 and 36 months was 98%, 90%,
and 85% in group I vs. 96%, 92%, and 92% in group II (P< 0.005). The primary and secondary
patency rates at 3 years were 92% vs. 98% (pZ .003) and 97% vs. 99% (pZ .04) for groups I
and II respectively. In group I, the Crossover Femoro-Femoral Bypass (CFFB) was responsible
for 3 major complications (2.4%) which occurred at 7, 12 and 57 months of follow-up. However,
the use of AUIS with CFFB did not independently increase the risk of major complications20 445 005; fax: þ33 320 445
e.fr (S. Haulon).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
A Comparison of the Mid-term Results in the Treatment of Abdominal Aortic Aneurysms 299during follow-up (HRZ 0.108; 95% CI: 0.007 to 1.637; pZ .11, Cox proportion model). In both
univariate and multivariate analysis, concomitant iliac arterial occlusive disease (IAOD) was
the only significant predictor of clinical failure in study population as a whole (ORZ 3.996;
95% CI: 1.996 to 7.921; p< .0001).
Conclusion: This study demonstrates that ABIS is associated with better results than AUIS in the
management of patients with AAA. Iliac artery occlusive disease was more frequently diag-
nosed in the AUIS group and this was significantly associated with a higher risk of complica-
tions, while the crossover graft itself was not. Nevertheless, the outcomes for both groups
are encouraging in this high risk population.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Endovascular surgery is gaining ground in the management
of abdominal aortic aneurysms (AAAs).1,2 The outcome
after endovascular aortic aneurysm repair (EVAR) has
improved. In part, this is because of an improved under-
standing of the limitations inherent to the endovascular
approach, and also of specific devices. Furthermore, this
experience has led to improvements in endovascular device
design.3 Aorto-uni-iliac stent-graft (AUIS) with adjunctive
cross-over femoro-femoral bypass (CFFB) was developed to
overcome the problems of adverse iliac anatomy and
narrow aortic bifurcations. To date, few studies have
addressed the question of EVAR in the population treated
using AUIS. There are few data to indicate factors predic-
tive of poor outcome.4e6 Despite early concerns with
respect to adjunctive CFFB patency, encouraging short-
term results have been reported in studies describing both
first- and second-generation devices. Nonetheless, mid- and
long-term data are still lacking and outcome differences by
comparison with patients treated by aorto-bi-iliac stent-
graft (ABIS) are rarely reported.
The purpose of this study was to report the outcome of
EVAR in a high-risk patient population and compare the
mid-term outcomes after AUIS and ABIS. Data were exam-
ined for factors predictive of failure.
Material and Methods
Between January 2003 and December 2006, 546 consecu-
tive patients underwent EVAR at two teaching French
hospitals (CHU de Nice and CHRU de Lille) using several
manufactured stent grafts (483 Zenith, 48 Talent, 10
Excluder and 5 AneurX). The data were collected
prospectively. This report specifically describes the
outcomes for the 447 patients who underwent elective
EVAR with Zenith stent grafts. All patients presenting with
AAA rupture (nZ 36) and those treated with other devices
(nZ 63) have been excluded from this retrospective anal-
ysis. Of the 447 patients, 124 (28%) received a Zenith AUIS
graft (group I) and 323 (72%) a ZENITH ABIS device (group
II). Analysis was performed on an ‘intention to treat’ basis.
All patients were deemed high risk for open AAA repair
according to the clinical criteria set by the AFSSAPS
(Agence Franc¸aise de Se´curite´ Sanitaire des Produits de
Sante´), which have been reported previously.7
The Zenith stent graft (Cook Incorporated, Bloomington,
IN, USA) is a modular, fully supported device available in two
different configurations: ABIS and AUIS. During the study
period, EVAR was performed based on the manufacturer’sinstructions for use. ABISwas the preferred option, but in the
setting of a narrow aortic bifurcation (diameter< 20 mm),
unilaterally small iliac artery (<7 mm), severe iliac tortu-
osity (tortuosity index8 1.5) or high-grade iliac angulation8
(grade 2e3). EVAR was performed using AUIS provided the
contralateral iliac system was large and straight enough to
accommodate the delivery system.
All patients underwent clinical examination, plain film
abdominal radiography and duplex scan or computed
tomography (CT) angiography at discharge and at 6-monthly
intervals for the first two postoperative years and annually
thereafter. Outcome measures included perioperative and
mid-term complication rates, freedom from re-intervention
and primary and secondary patency rates. The Kaplane
Meier method was used to determine patency and freedom
from re-intervention. Complications were reported as
‘major’ or ‘minor’ according to the system of classification
and grading described by Chaikof et al.9 The failure to
deploy a device at the intended location, presence of
a type I or III endoleak, graft thrombosis or infection,
aneurysm expansion, aneurysm rupture, conversion to open
repair, or death as a result of aneurysm rupture or aneu-
rysm-related treatment, were defined as clinical failures.10
Factors associated with mid-term clinical failures were
determined using univariate and multivariate logistic
regression analysis modelling. The factors examined were:
age, gender, medical co-morbidity, concomitant iliac
arterial occlusive disease (IAOD) according to the The
TransAtlantic InterSociety Consensus (TASC) classifica-
tion,10 ipsilateral distal landing zone diameter and
maximum aneurysm diameter at the time of repair. A p
value< 0.05 was considered significant.
Results
Patients’ demography
The patient characteristics are reported in Table 1. Apart
from the greater prevalence of concomitant IAOD in group
I, there were no significant differences between the groups
(Table 1). The IAOD was a TASC C or D lesion10 in 14 (11%)
group I patients vs. 17(5%) group II patients (pZ 0.02).
Technical considerations
Group I patients underwent CFFB with polyester woven
bypass grafts in 80 cases (65%) and with ringed polytetra-
fluoroethylene (PTFE) graft in 44 cases (35%). Prosthetic ilio-
Table 1 Patient demographic, anatomical and clinical data
Group I Group II P*
Ny 124 323
Demographics Age (mean SD) 75 yr 8.3 74 yr 8.6 .13
Gender: N Male: 115 Male: 313 .05
Female: 9 Female: 10
BMIz (mean SD) 27 4 28 5 .07
Morphology AAAx Max. diameter (mean SD) 55 mm 15 56 mm 11 .28
AAAx Proximal neck length (mean SD) 23 mm 8 24 mm 10 .65
Distal landing zone diameter** (mean SD) 14 mm 4 14 mm 4 .83
Co-morbidities Age> 80 yrs, N (%) 40 (32%) 92 (38%) .43
Coronaropathy, N (%) 48 (39%) 118 (37%) .7
Heart failure, N (%) 12 (10%) 23(7%) .37
Ejection fraction< 40%, N (%) 8 (6%) 24 (7%) .7
Severe aortic valve stenosis, N (%) 3 (2%) 4 (1%) .4yy
Respiratory insufficiency, N (%) 41 (33%) 83 (26%) .13
Renal insufficiency, N (%) 10 (8%) 33 (10%) .46
Hostile abdomen, N (%) 25 (20%) 93 (29%) .41
IAOD,zz N (%) 31 (25%) 43 (13%) .003
* P values, unless specified, are calculated from chi square or from Student’s T test.
y N: Total number of patients.
z BMI: Body Mass Index.
x AAA: Abdominal Aortic Aneurysm.
** Iliac mean diameter landing zone for the leg extension ipsilateral to the main body.
yy Fisher’s exact test.
zz Iliac arterial occlusive disease as evidenced on CTA or intraoperative angiography by the presence of: stenosis, occlusion, circum-
ferential calcification, or scattered calcifications over 25% of iliac arterial segment length.
300 E. Jean-Baptiste et al.femoral conduits were required for access in four group-II
patients (1%) versus none (0%) in group I. Percutaneous
transluminal angioplasty (PTA) with or without stent
deployment was performed as a prelude to the advancement
of delivery systems in nine (7%) patients in group I and in four
(1%) in group II. Serial dilation as described by Dotter11 was
performed in five (4%) in group I and nine (3%) in group II. In
group I, the distal landing zone of the AUIS was the common
iliac artery for 113 limbs (91%). In 11 patients, the AUIS was
landed in the external iliac artery (9%) because of iliac
bifurcation aneurysm (six cases), concomitant hypogastric
aneurysm (two cases) or inadvertently (three cases). In
group II, two ABIS (0.6%) were converted into AUIS with
adjunctive CFFB because of failed contralateral limb can-
nulation. The distal landing zone was the common iliac
artery for both ABIS limbs in 303 patients (606 limbs, 94%) and
for one ABIS limb in 19 patients (19 limbs, 3%). In these 19
patients, the indication for external iliac extension was iliac
bifurcation aneurysm (18 cases) or concomitant hypogastric
aneurysm (one case). In the latter patient, both ABIS limbs
were deployed in the external iliac artery because of bilat-
eral iliac bifurcation aneurysms. Considering both the
groups, patients with iliac bifurcation aneurysms (25 cases,
5.6%) or with concomitant hypogastric aneurysm (three
cases, 0.7%) underwent planned pre-EVAR hypogastric trunk
or selective hypogastric branch embolisation. During the
procedure, immediate conversion to open surgical repair
was performed in four patients (3%) in group I versus 0 (0%) in
group II (pZ 0.005). The main indications for surgicalconversion were an inability to advance the stent-graft
delivery system through the iliac arteries (three cases) and
mal-deployment of the stent graft (inadvertent supra-renal
deployment). The assisted primary technical success rate
was 94% (116/124) in group I and 99% (319/323) in group II
(pZ 0.002). Unplanned adjunctive procedures were
required in four (3.2%) and five (1.5%) operations in the group
I and group II patients, respectively (pZ 0.2). Specifically,
one patient from each group underwent hepatorenal bypass
to treat accidental right renal artery occlusion; iliac artery
rupture was treated using covered stents in two group-I
patients and by ilio-femoral bypass graft in two group-II
patients; three patients underwent balloon angioplasty with
bare-stent deployment to treat iliac dissections e one in
group I and two in group II.Postoperative complications
The postoperative complications are summarised in Table
2. In summary, major postoperative complications occurred
in 25 patients (6%): 13 patients from group I (10%) versus 12
patients from group II (4%) (pZ 0.005). Minor postoperative
complications were noted in six patients (5%) from group I
versus 12 patients (4%) from group II (pZ 0.59). The 30-day
mortality rate was 3.2% (nZ 4) in group I versus 1.5%
(nZ 5) in group II; (pZ 0.2). The causes of death in group I
were myocardial infarction (nZ 1), colonic ischemia
(nZ 1) and multi-organ failure (nZ 2). In group II,
Table 2 Post-operative complications
Group I, N (%) Group II, N (%) Whole cohort, N (%)
Major complications Death 4 (3.2%) 5 (1.5%) 9 (2%)
Myocardial infarction 3 (2.4%) 2 (0.6%) 5 (1.1%)
Retroperitoneal hematoma* 0 (0%) 3 (0.9%) 3 (0.7%)
Stroke 0 (0%) 2 (0.6%) 2 (0.4%)
Multi-organ failurey 2 (1.6%) 0 (0%) 2 (0.4%)
Colonic ischemia 2 (1.6%) 0 (0%) 2 (0.4%)
Chest infection 1 (0.8%) 0 (0%) 1 (0.2%)
Cardiac arrest from unknown origin 0 (0%) 1 (0.3%) 1 (0.2%)
Stent-graft limb thrombosisz 2 (1.6%) 0 (0%) 2 (0.4%)
Stent-graft mal-deployment 2 (1.6%) 1 (0.3%) 3 (0.7%)
Iliac artery rupture 2 (1.6%) 3 (0.6%) 5 (1.1%)
Iliac artery dissection 1 (0.8%) 2 (0.6%) 3 (0.7%)
Minor complications Groin hematoma or common femoral
false aneurysm
0 (0%) 8 (2.5%) 8 (1.8%)
Groin infection 2 (1.6%) 3 (0.9%) 5 (1.1%)
Lymphocele 3 (2.4%) 0 (0%) 3 (0.7%)
Lymph leak 1 (0.8%) 1 (0.3%) 2 (0.4%)
* Retroperitoneal hematomas were identified in patients who had panned iliac conduits (nZ 2) or to treat iliac artery rupture (nZ 1).
y Multi-organ failure was diagnosed in both of the group I patients who had intra-procedural iliac artery rupture treated with covered
stents.
z AUIS limb thromboses occurred during the procedure in the patients treated for iliac dissection and for iliac artery rupture. This was
resolved by immediate axillo-bi-femoral bypass as mechanical thrombectomy proved ineffective.
Table 3 Endoleaks depicted during follow-up
Endoleaks Group I, N (%) Group II, N (%)
Type I (proximal) 3 (2.4%) 3 (0.9%)
Type I (distal) 2 (1.6%) 5 (1.5%)
Type IIx 1 (0.8%) 3 (0.9%)
Type III 1 (0.8%) 0 (0%)
Type IV 0 (0%) 0 (0%)
x Type II endoleaks with increased AAA maximum diameter.
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(nZ 1), unexplained fatal cardiac arrest (nZ 1) and intra-
procedural iliac rupture (nZ 1). This last patient died
before any salvage procedure could be performed. The
presence of iliac TASC C and D lesions was associated with
the occurrence of major post-operative complications in
both the groups (35% vs. 3%; ORZ 14.94; 95% CI: 5.75e
38.78; p< 0.0001).
Medium-term morbidity
The median duration of follow-up was 24 months (range: 1e
60 months). Minor late complications occurred in nine (7%)
group-I patients and in 15 (5%) group-II patients. These were
all type II endoleaks, which were identified, but without
associated aneurysm growth. They were all monitored, but
required no delayed intervention. Complications requiring
secondary procedures were identified in 14 (11%) group I and
15 (5%) group II patients (pZ 0.01). These 29 (6.5%)
complications comprised endoleaks (nZ 18, 4%), occlusive
CFFB or stent-graft limb complications (nZ 10, 2.2%) and
combined CFFB and AUIS infection (nZ 1, 0.2%). Actuarial
freedom from re-intervention was 98%, 90% and 85% in group
I, and 96%, 92% and 92% in group II at 12, 24 and 36 months of
follow-up, respectively. Table 3 summarises the late endo-
leaks identified that required secondary procedures. With
one exception, all patients with type I and type III endoleaks
were successfully managed using secondary endovascular
procedures. The exception was a group-I patient with
a proximal type I endoleak, who underwent urgent open
surgical conversion for AAA rupture but died perioper-
atively. Four patients (one from group I and three from group
II) with type II endoleaks and increasing AAA size were
managed using lumbar artery embolisation. No graft
migrations were identified in either group. One group Ipatient with CFFB and AUIS infection underwent successful
secondary open surgical conversion. There were no
instances of stent-graft infection in the group II patients. Six
patients in group I and four in group II developed stent-graft
limb occlusions or stenoses (three stent-graft limb throm-
bosis in each group, one stent-graft limb stenosis in group I,
two CFFB anastomotic stenoses in group I and one iliac
artery stenosis distal to the landing zone in group II). Table 4
summarises the limb and CFFB complications and their
treatments and outcomes for both the groups. The actuarial
primary patency rate was 94%, 92% and 92% in group I
compared with 99%, 98% and 98% in group II (pZ 0.003) at
12, 24 and 36 months, respectively (Fig. 1A). The 3-year
actuarial secondary patency rate was 97% and 99% in group I
and group II (pZ 0.04), respectively; (Fig. 1B).
In group I, the choice of bypass graft material (ringed
ePTFE or woven polyester) did not affect the incidence of
complications (pZ 0.37). In total, the CFFBs were of
themselves responsible for three major complications
(2.4%), which occurred 7, 12 and 57 months after surgery.
The CFFB grafts were the site of the underlying stenosis
leading to device limb occlusion (nZ 2) or was the primary
site of infection (nZ 1). Nevertheless, the use of AUIS and
Figure 1 Kaplan Meier analysis of primary (A) and secondary
patency rate (B) with the standard error bars.
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complications during follow-up (Cox proportion model
hazard ratioZ 0.108; 95% CI: 0.007e1.637; pZ 0.11).
Predictors of failure
Clinical failures were noted in 22 (18%) of group I patients
and 19 (6%) of group II patients (pZ 0.0001). For the study
population as a whole, univariate analysis identified the
presence of TASC C and D iliac artery lesions to be associ-
ated with clinical failure (p< 0.0001). There was no such
association with gender (pZ 0.83), ipsilateral distal landing
zone diameter (pZ 0.09) or pre-operative maximum
aneurysm diameter (pZ 0.61). There was no association
with any co-morbidity (age> 80 years; (pZ 0.96), coronary
artery disease (pZ 0.34), heart failure (pZ 0.63), respi-
ratory insufficiency (pZ 0.81) or chronic renal insufficiency
(pZ 0.10)). In multivariate logistic regression analysis,
taking into account factors in univariate analysis with
p-value 0.10, neither chronic renal insufficiency
(ORZ 1.872; 95% CI: 0.747e4.690; pZ 0.18) nor distal
landing zone diameter (ORZ 1.062; 95% CI: 0.974e1.157;
pZ 0.17) were associated with clinical failure. Concomi-
tant TASC C and D iliac artery lesions (ORZ 3.996; 95% CI:
1.996e7.921; p< 0.0001) were confirmed to be the only
significant predictors of clinical failures.
Discussion
We have reported the results of EVAR, comparing outcome
after ABIS with that after AUIS, in high-risk patients with
AAA. This is not a randomised, blinded controlled trial. AUIS
were used selectively in patients with adverse anatomy,
who were deemed unsuitable candidates for ABIS or open
surgery. The patients selected for AUIS represented
a greater technical challenge than those suitable for ABIS in
that there was a greater preponderance of TASC C and D
iliac artery lesions. This is an important selection bias and
largely explains our findings. There has been no attempt to
match patients with similar anatomy or other technicalTable 4 Stent-graft limb and CFFB adverse events during follow
Adverse events Underlying condition
Group I
Limb thrombosis Limb kinking
Limb thrombosis Evolving distal IAOD**
Limb thrombosis Evolving distal IAOD**
Limb stenosis Limb kinking
CFFBzz anastomotic stenosis Evolving FAODxx
CFFBzz anastomotic stenosis Evolving FAODxx
Group II
Limb thrombosis Limb kinking
Limb thrombosis Limb kinking
Limb thrombosis Evolving distal IAOD**
Limb stenosis Evolving distal IAOD**
** IAOD: Iliac arterial occlusive disease.
yy PTA: Percutaneous transluminal balloon angioplasty.
zz CFFB: Crossover femoro-femoral bypass.
xx FAOD: Femoral arterial occlusive disease.features. Direct like-for-like comparison is therefore
invalid, and it is not possible to conclude that ABIS devices
perform better than AUIS procedures. Nevertheless, this
report is the most comprehensive attempt to examine the
outcome differences between AUIS and ABIS to date.
We report that the short-term operative mortality for
both AUIS and ABIS is within the range generally reported-up
Treatment Outcome
Thrombectomyþ bare stent Favorable
Thrombectomyþ bare stent Blue toe syndrome
Axilo-bi-femoral bypass Favorable
PTAyy þ bare stent Favorable
Redo anastomosis Favorable
PTAyy Recurrence (repeat PTAyy)
Thrombectomyþ bare stent Favorable
CFFBzz graft Favorable
CFFBzz graft Favorable
PTAyy þ bare stent Favorable
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offer treatment to a greater range of patients with aneu-
rysms, we have employed AUIS for those with more severe
IAOD. Nevertheless, our study has shown that patients with
challenging iliac artery anatomy have a relatively greater
risk of perioperative morbidity. Graft manufacturers are
currently developing devices with delivery systems incor-
porating hydrophilic coatings. It is hoped that this generation
of devices will prove better able to negotiate small and
tortuous iliac arteries, extending the range of ABIS thereby
reducing the morbidity associated with AUIS. An alternative
approach is the use of conduits anastomosed to the common
iliac arteries to circumnavigate the problems of small-
calibre or diseased external iliac vessels. However, this
approach has its own morbidity as reported in this study.
During follow-up, secondary procedures were required to
treat device or EVAR-specific complications in both groups. In
general, the incidence of endoleaks compares favourably
with that reported previously.19e21 However, AUIS with
adjunctive CFFB yielded lower primary and lower secondary
patency rates compared to ABIS. One explanation is the
greater frequency with which AUIS were deployed into the
external iliac artery, a factor associated with a higher risk of
complications, as reported byHinchliffe et al.5 In this regard,
the use of adjunctive bare stents may be a useful strategy to
preserve graftelimb patency in these cases.22 A recent
randomised controlled trial has shown that CFFB (extra-
anatomical bypass) results in a higher morbidity and lower
patency rates thananatomicalbypass inpatientswith IAOD.23
Our 3-year primary and secondary patency rates for patients
treated using AUIS are comparable or better than those
usually reported for CFFB in the management of isolated
IAOD.23e25 These findings are consistent with those of several
previous studies describing CFFB in the specific setting of
EVAR using AUIS.5,6,11,17,26e29 An alternative explanation for
lower patency of AUIS on comparison with ABIS is simply the
presence of more severe occlusive iliac artery disease in
patients whose anatomy and disease necessitated AUIS.
Previous reports indicate that patients with extensive
unilateral iliac lesions also harbour contralateral disease.21
These patients may be at a greater risk of developing occlu-
sion at the level of, or distal to, the distal AUIS EVAR landing
zone. In addition, stent-graft limb occlusion can be caused by
kinking.6,24,30e33 Both AUIS and ABIS limb kinking have been
reported.34 Several authors have suggested that this is
a consequence of post-treatment aneurysm sac regression
and consequent device migration.35,36 However, this report
specifically details only theuseof a device (ZENITH) that has
been reported previously as being particularly stable with
respect to migration.37,38 Finally, iliac artery tortuosity is by
itself apotential causeof limbkinkingandocclusion. If so, it is
expected that that this should be more common with
unsupported limbs.6 However, existing data suggest that it
occurs despite bare-stent-supported limbs deployed in
severely tortuous iliac arteries.5,22,35
Adverse iliac and unfavourable proximal neck anatomy
persist as the primary causes of EVAR failure and the oblig-
atory use of open surgical repair.39 Unfavourable aortic neck
anatomy can be addressed by using branched and fenes-
trated solutions. It is likely, therefore, that problems asso-
ciated with access vessels and iliac landing zones will prove
pre-eminent as the exclusion criteria for EVAR.In this study, AUIS has proved a successful strategy in the
treatment of AAA in patients otherwise untreatable with
either ABIS or open surgery. Both univariate and multivar-
iate analyses have shown that patients with IAOD have
a relatively greater risk of poor outcome, although
successful in the majority. These data may be used to
support a policy of less-liberal use of EVAR in patients with
advanced IAOD. An alternative is the more liberal use of
iliac conduits to facilitate ABIS. This specific issue deserves
prospective evaluation.
Conclusion
Our experience shows that patients with challenging iliac
anatomy and disease were treated with AUIS, although at
higher operative risk and lower medium-term primary
patency rate (resulting in greater re-intervention rates)
when compared with patients treated with ABIS. Never-
theless, mid-term secondary patency rates are acceptable.
As a strategy, AUIS has enabled treatment of patients with
AAA who were not candidates for ABIS or open surgery.
Improved devices, or the use of iliac conduits for access,
may allow more of these patients to be treated using ABIS,
possibly with better results.
The significance of this study may lie in its large sample
size and that it reflects a real-world experience. We suggest
that our experience has value for other practitioners in the
field, providing reassurance that both techniques are of
value and allows for more informed patient counselling.
In summary, we advocate that ABIS is the technique of
first choice for patients with suitable anatomy, but AUIS is
a good alternative for unfit patients with challenging iliac
anatomy.
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